Abstract
Background: 68Ga-PSMA-11 PET is used to stage patients with prostate cancer. We performed an updated meta-analysis, which separates imaging at the time of diagnosis and that at the time of biochemical recurrence, and focuses on pathology correlation in both populations. Methods: We searched MEDLINE and EMBASE databases using the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. A random effect model and a hierarchical summary receiver operating characteristic model was used to summarize the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for pelvic lymph nodes in initial staging compared to pathology at prostatectomy, and the PPV for lesions with pathologic correlation in those with biochemical recurrence. We also summarized the detection rate of 68Ga-PSMA-11 in those with biochemical recurrence stratified by PSA at time of imaging. Results: The meta-regression analysis of 68Ga-PSMA-11 in at initial staging demonstrated a sensitivity and specificity compared to nodal pathology at prostatectomy was 0.74 (0.51, 0.89), 0.96 (0.85, 0.99). At biochemical recurrence, the PPV was 0.99 (0.96, 1.00). The detection rate was 0.63 (0.55, 0.70) with a PSA less than 2.0, and 0.94 (0.91, 0.96) with a PSA greater than 2.0. Conclusion: 68Ga-PSMA-11 performed well for the localization of metastatic prostate cancer at initial staging patients and at the time of biochemical recurrence.
- Copyright © 2018 by the Society of Nuclear Medicine and Molecular Imaging, Inc.